Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

29.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
News headline image
2 Stocks Down More Than 30% to Buy Right Now ↗
These stocks have suffered as the demand for their biggest product -- the coronavirus vaccine -- waned. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Dow Nearly 100 Points Lower Amid Slumping Home Sales ↗
Via Talk Markets
Topics Stocks
News headline image
Why Is Moderna Stock Trading Lower On Wednesday? ↗
The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in... 
Via Benzinga
News headline image
Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots ↗
After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease. 
Via Investor's Business Daily
News headline image
Moderna's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $900 Today ↗
 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on MRNA Options ↗
 
Via Benzinga
News headline image
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight ↗
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
What's Going On With Eli Lilly Stock On Tuesday? ↗
Eli Lilly collaborates with Microsoft-backed OpenAI to leverage generative AI for developing novel antimicrobials targeting drug-resistant pathogens. This partnership supports Lilly's commitment to... 
Via Benzinga
Topics Artificial Intelligence
News headline image
S&P 500, Nasdaq Lurking Below Record Highs ↗
Stocks are scattered this afternoon, as investors digest a weaker-than-expected retail sales reading from May. 
Via Talk Markets
Topics Stocks
News headline image
Smart Money Is Betting Big In MRNA Options ↗
 
Via Benzinga
News headline image
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Via ACCESSWIRE
News headline image
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment ↗
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
News headline image
The RBA Kept Interest Rates On Hold And Remained Hawkish ↗
The Reserve Bank of Australia kept the cash rate at 4.35% at its June meeting, leaving borrowing costs unchanged for the fifth time. 
Via Talk Markets
News headline image
OpenAI And Color Health Develop AI-Driven Cancer Care Solutions: Report ↗
OpenAI and startup Color Health have developed an AI assistant, named 'copilot', to support physicians in creating personalized cancer care plans, emphasizing the tool's role in augmenting rather than... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
News headline image
Moderna Just Gave Investors Another Reason to Buy the Stock ↗
The company's post-pandemic prospects are getting brighter. 
Via The Motley Fool
News headline image
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Via ACCESSWIRE
News headline image
7 Struggling Stocks to Sell Before July 2024 ↗
The stock market is riding high for now. But even a roaring bull market can't save these seven stocks to sell. 
Via InvestorPlace
News headline image
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants ↗
After the FDA's authorization of a Covid19 booster shot, you may want to consider adding these vaccine stocks to your portfolio. 
Via InvestorPlace
News headline image
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
What's Going On With Moderna Stock Monday? ↗
Moderna said its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, met its primary endpoints. 
Via Benzinga
News headline image
Nike, Merck, General Motors, And More: CNBC's 'Final Trades' ↗
Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of Cerity Partners picks General Motors, while Jason Snipe of Odyssey Capital... 
Via Benzinga
News headline image
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK ↗
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
News headline image
Why Moderna Stock Is a No-Brainer Buy Right Now ↗
This messenger-RNA pioneer should be able to keep its rebound going. 
Via The Motley Fool
News headline image
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Via ACCESSWIRE
News headline image
3 Reasons to Buy Moderna Stock ↗
The biotech hasn't said its last word. 
Via The Motley Fool
News headline image
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season ↗
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.